How glypicans affect eye pressure and glaucoma risk
Role of Glypicans in Trabecular Meshwork Function, IOP, and Glaucoma
Researchers are looking at whether cell-surface proteins called glypicans control fluid drainage in the eye and contribute to high eye pressure in people at risk for glaucoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11181577 on NIH RePORTER |
What this research studies
This work focuses on the trabecular meshwork, the tissue that drains fluid from the eye, and examines how glypican proteins (especially GPC4) change cell contraction, adhesion, and extracellular matrix that can raise intraocular pressure. Scientists will use human trabecular meshwork cells and related models to study the molecular signals that link steroid exposure and other triggers to harmful cell behavior. The team aims to identify new molecular targets that could lead to IOP-lowering drugs with fewer side effects than current options. Results could guide future patient-focused studies and new therapies for people with ocular hypertension or glaucoma.
Who could benefit from this research
Good fit: People with ocular hypertension or open-angle glaucoma, and those who develop high eye pressure after steroid treatment, would be the most likely to benefit from or be recruited into related future studies.
Not a fit: Patients with vision loss unrelated to intraocular pressure or those needing immediate treatment for advanced optic nerve damage are unlikely to gain direct benefit from this basic science work.
Why it matters
Potential benefit: If successful, this research could point to new drug targets that lower eye pressure more safely and help prevent vision loss from glaucoma.
How similar studies have performed: Other treatments that target cell contractility and adhesion (for example ROCK inhibitors) have successfully lowered eye pressure, while targeting glypicans is a newer and largely untested approach.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Rao, P Vasantha — Duke University
- Study coordinator: Rao, P Vasantha
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.